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Taking advantage of solvate formation to modulate
drug-drug ratio in clofaziminium diclofenac salts†
Laurie Bodart,∗a Maria Prinzo,b Amélie Derlet, a Nikolay Tumanov, a and Johan
Wouters∗a
Non-steroidal anti-inflammatory drugs, such as diclofenac, are gaining attention as repurposed
compounds for the treatment of multi-drug resistant tuberculosis. In this study, salts combining di-
clofenac with clofazimine, are prepared by solvent crystallization and by liquid-assisted grinding.
Diclofenac anion possesses an H-bond acceptor which can strongly interact with protic solvent
molecules. In this context, selected solvents (protic, aprotic and solvents with increasing molec-
ular volume) are screened in order to investigate solvent impact on crystallization of solvated or
unsolvated salt of clofazimine with diclofenac in 1:1 ratio. Five solvated salts and one unsolvated
salt were successfully crystallized. The ability of the diclofenac anion to interact with a protic
molecule is also exploited in order to crystallize a cocrystal of salt with drug:drug ratio different
from 1:1. Structures of two solvated cocrystal of salts (with acetonitrile and ethylacetate) and two
polymorphs of an unsolvated cocrystal of salt combining clofazimine with diclofenac in 1:2 ratios
are determined.
1 Introduction
Pharmaceutical compounds are often exposed to solvents (or
their vapors) during manufacturing (i.e. at the steps of crys-
tallization, wet granulation, spray drying or lyophilization)1,2.
Organic compounds including pharmaceuticals are often found
in the form of solvates3,4. However, crystalline changes induced
by solvate formation or solvent evaporation from the structure
can considerably affect the physico-chemical properties of the
compounds. Although, in the pharmaceutical industry, solvate
formation can sometimes be beneficial to the properties of
drugs (e.g., indinavir shows better bioavailability when in the
form of a sulfate ethanol solvated form1,5,6), in many other
cases it is a nuisance: for instance, if the solvent is toxic or
the solvated form exhibits undesired physicochemical and/or
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mechanical properties. Thus, selecting a proper solvent which
would present a reduced probability of solvate formation is of
crucial importance for drug manufacturing7.
Several factors have been investigated for their impact on
solvate formation. The two most important ones have been
identified as solvent-solute affinity and molecular size and shape
of the solvent8,9. The first parameter, among other factors,
depends on hydrogen bonding and aromatic interaction abilities
of the molecule. The second parameter is in correlation with the
concept of packing efficiency, since solvent presenting low affinity
for a compound can still be incoporated into its structure if it
allows a better packing8,10. While various solvents, depending
on their molecular volume, size and shape, may lead to different
crystal packings, it is also possible that bulky molecules of the
compound itself fail to form efficient packing and thus may
incorporate solvent molecules in order to improve it. The
presence of hydrogen bonding groups tends to promote inclusion
of polar solvents by strong and specific interactions11. Despite
identification of certain factors contributing to solvate formation,
theoretical solvate prediction is challenging and research in this
area is still ongoing9,10.
In this study, we focus on the solvated salts of a drug-drug sys-
tem comprising clofazimine and diclofenac. Clofazimine (CFZ),
exhibits antimycobacterial and anti-inflammatory properties
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Fig. 1 Scheme of the chemical species observed in the crystal structures of solvated and unsolvated salts/cocrystal of salts: (a) clofaziminium cation,
(b) diclofenac anion, (c) diclofenac, (d) methanol, (e) ethanol, (f) acetonitrile, (g) water, (h) salicylaldehyde, (i) propiophenone and (j) ethylacetate.
multidrug-resistant tuberculosis12–17. Diclofenac (DCF) belongs
to the class of non-steroidal anti-inflammatory drugs (NSAIDs)
that has been recently proposed as a host-directed therapy in
the treatment of tuberculosis owing to its antitubercular prop-
erties18–22. Several studies showing the ability of clofazimine
(pKa: 9.2923) to form salts with organic and inorganic acids24–28
point that combining CFZ with DCF in a drug-drug salt should
be achievable. Several solvates were previously reported for
clofaziminium as well as diclofenac salts26,28 and strong H-bond
interaction between DCF and solvent molecules have been
reported29. Solvate formation is thus also expected with protic
solvents during the preparation the drug-drug CFZ-DCF salts.
In our experiments, as expected, diclofenac tended to bind pro-
tic solvents and incorporate them into structure, thereby resulting
in the solvated form of the CFZ-DCF 1:1 salt. Our further hypoth-
esis was that diclofenac molecule, being also protic, should be
able to compete with the solvent molecule for that binding site
and thus instead of a solvated 1:1 form lead to a 1:2 CFZ-DCF
cocrystal of salt, with diclofenac molecule being connected to di-
clofenac anion. To verify this and also to see whether an unsol-
vated 1:1 salt can also be obtained, we have selected a number of
aprotic solvents with increasing molecular volume, which due to
their chemical nature should have a lower probability of binding
to diclofenac. Experimenting with various solvents, we obtained
in total five solvated 1:1 forms, two solvated 1:2 forms, one un-
solvated 1:1 CFZ-DCF salt and two unsolvated 1:2 cocrystal of
salt, thus proving that selecting a proper solvent is essential in
crystallization processes and might be key to obtaining desired
structures.
2 Materials and methods
2.1 Materials
Clofazimine and diclofenac were respectively purchased from
TCI Europe N.V. (Zwindrecht, Belgium) and Sigma Aldrich
(Schnelldorf, Germany). Propiophenone, salicylaldehyde and
ethylacetate (Sigma Aldrich, Schnelldorf, Germany), acetonitrile
(Thermo Fisher Scientific, Geel, Belgium), methanol (ChemLab,
Zedelgem, Belgium), ethanol (Merck, Overijse, Belgium), N, N’-
dimethylformamide and poly(ethyleneglycol) of average MW 200
(Acros Organics, Geel, Belgium) were used without further purifi-
cation as crystallization solvents.




(1:1:1) and CFZNH+-DCF− (1:1) can be obtained by grinding
75.0 mg, 0.158 mmol of CFZ with 46.9 mg, 0.158 mmol
of DCF in presence of 30 µL of MeOH, EtOH and EtOAc
respectively (liquid-assisted grinding). CFZNH+-DCF−-DCF
(1:1:1) (polymorph I), CFZNH+-DCF−-DCF-MeCN (1:1:1:2)
and CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) are prepared by
grinding 75.0 mg (0.158 mmol) of CFZ with 93.8 mg (0.316
mmol) of DCF in presence of 30 µL of EtOH, MeCN and EtOAc
respectively. Crystals of CFZNH+-DCF−-DCF (1:1:1) (polymorph
I), CFZNH+-DCF−-DCF-MeCN (1:1:1:2) and CFZNH+-DCF−-
DCF-EtOAc (1:1:1:1) were obtained by recrystallization of the
corresponding powder (CFZ-DCF 1:2 LAG EtOH, LAG MeCN and
LAG EtOAc) in ethanol, acetonitrile and ethylacetate respectively
(Figure 2). All ball milling experiments were performed at 30
Hz, during 90 minutes (samples were homogenized each 30
minutes) with a Retsch MM 400 Mixer Mill apparatus. Powders
were inserted in 2 mL Eppendorf tubes with eight stainless steel
balls (7 balls of 2 mm diameter and 1 ball of 3 mm diameter)
and were then placed in two grinding jars in which up to 5 Ep-
pendorf tubes can be installed. Powder of CFZNH+-DCF−-DCF
(1:1:1) (polymorph II) cocrystal of salt is obtained by desolvata-
tion (heating at 130 - 140 °C) of CFZNH+-DCF−-DCF-MeCN
(1:1:1:2) or of CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) (obtained
by liquid-assisted grinding, Figure 2).
2.2.2 Solvent evaporation method.
Powders consisting of an equimolar ratio of clofazimine (37.4
mg, 0.0790 mmol) and diclofenac acid (23.4 mg, 0.0790 mmol)
were stirred in the selected solvent (MeCN, MeOH, EtOH, DMF)
until complete dissolution and left for slow evaporation at
room temperature (20-25 °C). Crystals of CFZNH+-DCF−-MeOH
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(1:1:0.74), CFZNH+-DCF−-EtOH (1:1:1) and CFZNH+-DCF−-
MeCN-H2O (1:1:1:2) were obtained in MeOH, EtOH and MeCN
respectively. Crystals of CFZNH+-DCF−-DCF-MeCN (1:1:1:2)
and of CFZNH+-DCF−-DCF (1:1:1) (polymorph II) were ob-
tained in MeCN and PEG 200 respectively, by the same method
but from a powder consisting of clofazimine (37.4 mg, 0.0790
mmol) and diclofenac acid (46.8 mg, 0.158 mmol) in 1:2 molar
ratio.
Given the low vapor pressure at room temperature (20-25 °C)
of propiophenone and salicylaldehyde and the quite good solu-
bility of CFZ and DCF in these solvents, crystallization by solvent
evaporation is quite difficult. For this reason, the 1:1 powder mix-
ture of CFZ and DCF was not fully dissolved in these solvent (i.e.
an excess powder was placed in the solvent and left at room tem-
perature for crystallization) to give CFZNH+-DCF−-PPP (2:2:5)
and CFZNH+-DCF−-SAL-H2O (4:4:9:1).
2.3 Single-crystal X-ray diffraction (SCXRD)
Data collection was performed with an Oxford Diffraction Gem-
ini Ultra R system equipped with a four-circle kappa platform
and a Ruby CCD detector, using Cu Kα (λ = 1.54184 Å) radi-
ation. Full data sets were collected either at 295 K (CFZNH+-
DCF−-MeOH (1:1:0.74), CFZNH+-DCF− (1:1), CFZNH+-DCF−-
DCF-MeCN (1:1:1:2), CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) and
CFZNH+-DCF−-DCF (1:1:1) (polymorphs I and II)), at 100 K
(CFZNH+-DCF−-MeCN-H2O (1:1:1:2) and CFZNH+-DCF−-SAL-
H2O (4:4:9:1)) or at both temperatures (CFZNH+-DCF−-EtOH
(1:1:1) and CFZNH+-DCF−-PPP (2:2:5)). Low-temperature
data collection was necessary for CFZNH+-DCF−-MeCN-H2O
(1:1:1:2) because crystals are unstable at room temperature.
Crystals of CFZNH+-DCF−-SAL-H2O (4:4:9:1) were stable at
room temperature but disorder in the structure could not be re-
solved without low-temperature data collection. First, analyti-
cal numerical absorption correction implemented using a mul-
tifaceted crystal model based on expressions derived by Clark
& Reid30 was performed using CrysAlis PRO31. Then, em-
pirical absorption correction was applied, within CrysAlis PRO,
using spherical harmonics32 as implemented in the SCALE3
ABSPACK scaling algorithm. Dual-space method implemented
within SHELXT 33 was used for structure solution. Refinement
was performed within Olex2 34 and ShelXle35 using the least-
square method (SHELXL-2016/636). Anisotropic refinement was
performed for non hydrogen atoms. If not involved in strong H-
bonds, hydrogen atoms were refined as riding atoms with dis-
placement spheres fixed to 1.2 times that of the parent atom
(1.5 for methyl groups). Positions of H atoms involved in strong
H-bond were located in Fourier map and refined (except for
disordered MeOH molecule in the structure of CFZNH+-DCF−-
MeOH (1:1:0.74), disordered EtOH molecule in the structure
of CFZNH+-DCF−-EtOH (1:1:1) (data collected at 295 K) and
for disordered salicylaldehyde molecules and the water molecule
in CFZNH+-DCF−-SAL-H2O (4:4:9:1)). The solvent molecules
are disordered in several structures. More particularly, the
methanol molecule in CFZNH+-DCF−-MeOH (1:1:0.74); all sol-
vent molecules in CFZNH+-DCF−-PPP (2:2:5) (data collected at
295 K); one molecule of propiophenone (which is located close
to an inversion center) in CFZNH+-DCF−-PPP (2:2:5) (data col-
lection at 100 K); five salicylaldehyde molecules (which are not
involved in intermolecular H-bonds) in the structure of CFZNH+-
DCF−-SAL-H2O (4:4:9:1); the ethanol molecule in the structure
of CFZNH+-DCF−-EtOH (1:1:1) for which data were collected
at 295 K and one MeCN molecule in CFZNH+-DCF−-DCF-MeCN
(1:1:1:2) are disordered.
2.4 Powder X-ray diffraction (PXRD)
Powder diffraction data were collected with Cu Kα radiation (λ
= 1.54184 Å) from 4 to 40° 2θ angle (step size of 0.0167°) on a
PANalytical X’PERT PRO Bragg-Brentano diffractometer with an
X’Celerator linear detector. Tension and current of the generator
were set to 45 kV and 30 mA for data collection.
Variable-temperature PXRD (VT-PXRD) experiments were con-
ducted on the same diffractometer equipped with an Anton-Paar
TTK 450 system. Data were collected at 25 °C and then from
30 °C to 140 °C with data collection every 10 °C.
2.5 Thermogravimetric analysis (TGA) and differential scan-
ning calorimetry (DSC)
Thermal properties of powders obtained by liquid-assisted grind-
ing and corresponding to determined structures were analysed
using a Mettler Toledo TGA/DSC 3+ apparatus. Around 5-10 mg
of solid samples were placed in 100 µL aluminium pans. The
analysis was performed from 25 °C to 250 °C with a heating
rate of 10 °C/min and using nitrogen (60 mL/min) as purge gas.
TGA/DSC results were analysed using the STARe software (ver-
sion 16.20)
2.6 Structure visulization, crystal packing comparison and
solvent molecular volume calculations
Structures and crystal packings were visualized and compared
using Mercury37. Voids were calculated with the ‘Voids’ option
within Mercury37 with a probe radius of 1.2 Å and an approx-
imated grid spacing of 0.1 Å. Images were generated with de
same program. Crystal packings were more specifically compared
using the ‘Crystal packing similarity’ tool in Mercury37. Packing
shell size, distance and angle tolerance parameters were set to
15 molecules, 30% and 30° respectively. Moreover, molecular dif-
ferences and structure inversion were allowed while bond types,
H-atom position, atoms’ hydrogen counts and atoms bond counts
were ignored. As structures contain different solvents, smallest
molecular component was ignored for crystal packing compari-
son. Solvent molecular volumes were determined with the free
Molinspiration molecular property calculation service38.
3 Results and discussion
The current work includes two parts. In the first part, we have
investigated solvated and unsolvated forms of CFZ-DCF 1:1 salt.
The second part is focused on the ability of diclofenac anion to
bind diclofenac molecule instead of a solvent molecule (a phe-
nomenon often observed in 1:1 salts) to obtain a 1:2 CFZ-DCF
cocrystal of salt. To obtain drug-drug salts, clofazimine and di-
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Fig. 2 Summary of performed experiments and associated results. LAG: liquid-assisted grinding, DMF: N, N ’-dimethylformamide PPP: propiophenone,
SAL: salicylaldehyde, MeCN: acetonitrile, EtOH: ethanol, MeOH: methanol, EtOAc: ethyl acetate, PEO: polyethylene glycol.
clofenac were subjected to solvent evaporation crystallization and
liquid-assisted grinding (Figure 2). Below and for each part of the
work, we will first present structural analysis of the new crystal
structures combining clofazimine with diclofenac (Figure 1 and
Figures S1 and S2 (labelling)†) and discuss the impact of solvent
selection on the crystallization outcome.
3.1 Investigation of CFZ-DCF 1:1 salts
The solvents used in the first part of this work were selected based
on their ability to interact with the solute (CFZ cations and DCF
anions) via hydrogen bonding or other weak interactions and on
their molecular size and shape - two main parameters influencing
the formation of solvates. First, we selected a series of protic sol-
vents of increasing molecular volume (MeOH, EtOH, salicylalde-
hyde) in order to investigate the impact on solvate formation of
those solvents that are capable of forming H-bond with diclofenac
anion. In addition to H-bonds, the aromatic system of salicylalde-
hyde could also be involved in stacking interactions with clofazi-
minium cation and/or diclofenac anion. Second, we took aprotic
solvents of variable molecular volume (MeCN, DMF, EtOAc, pro-
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piophenone) in order to study the effect of solvents that do not
have the ability to interact with diclofenac anion through H-bond.
Propiophenone, that could potentially interact with CFZNH+ and
DCF− through stacking has also been included among the se-
lected aprotic solvents. Below we present structural analysis of
the 1:1 solvated and unsolvated CFZ-DCF salts that were obtained
using aforementioned solvents followed by the discussion of the
solvent impact on crystallization outcome.
3.1.1 Structural analysis
3.1.1.1 CFZNH+-DCF−-MeOH (1:1:0.74) solvated salt crys-
tallizes in C2/c space group (Table 1). The asymmetric unit
contains one clofaziminium cation, one diclofenac anion and
methanol molecule, which is disordered over two positions (one
position is located around C2 axis). A R12(7) motif is ob-
served between clofazimine and diclofenac (N4−H4· · ·O1 and
N3−H3· · ·O1 charge-assisted H-bonds, Figure 3 (a) and Table
S2†). A weaker H-bond is also observed between CFZNH+ and
DCF− (N4−H4· · ·O2, Figure 3 (a) and Table S2†). Methanol (po-
sition with an occupancy of 0.5) interacts with diclofenac through
H-bond (O3A−H3OA· · ·O2, Figure 3 (a) and Table S2†). An in-
tramolecular N5−H5· · ·O1 H-bond is also present within the di-
clofenac anion. A weak C24−H24· · ·O2 H-bond stabilizes dimers
of CFZNH+-DCF−-MeOH trimolecular assemblies (Figure 3 (b)).
Fig. 3 (a) H-bonds between clofaziminium, diclofenac and methanol
in CFZNH+-DCF−-MeOH (1:1:0.74) (MeOH disorder not shown) and
(b) weak C24−H24· · ·O2 H-bond stabilizing dimers of CFZNH+-DCF−-
MeOH trimolecular assemblies and head-to-tail stacking of these assem-
blies (planes (light blue) and centroids (red) are calculated with C5 C6
C11 and C12 atoms). H-bonds are represented by blue dashed lines.
These dimers are further stacked in a head-to-tail fashion (Fig-
ure 3 (b), centroid-centroid distance of 3.623(2) Å, orthogonal
projection distance of 3.378(1) Å and horizontal displacement of
1.311 Å). This salt can also be prepared by liquid-assisted grind-
ing of CFZ with DCF (in 1:1 molar ratio) and with MeOH as sol-
vent (Figure S3 (a)†). TG/DSC analysis of the powder indicates
a weight loss of 2.6% between 30 and 150 °C (calculated MeOH
content: 2.99%) (Figure S4 †). The powder of CFZNH+-DCF−-
MeOH (1:1:0.74) melts at 118 °C (as confirmed by an analysis
performed on a a Koffler apparatus). Complete desolvatation is
difficult to achieve before melting of the powder (at 100 °C, the
solvate is still present) and the crystalline phase obtained upon
heating of CFZNH+-DCF−-MeOH (1:1:0.74) at 110 °C could not
be identified (Figure S5†).
3.1.1.2 CFZNH+-DCF−-EtOH (1:1:1) solvated salt crystal-
lizes in P1̄ triclinic space group (Table 1). The asymmetric unit
consists of the clofaziminium cation, diclofenac anion and one
solvent molecule (EtOH). This structure was determined at 295
and 100 K. At 295 K, EtOH molecule is disordered over two
Fig. 4 (a) H-bonds between clofaziminium, diclofenac anion and ethanol
in the structure of CFZNH+-DCF−-EtOH (1:1:1) solvated salt. (b)
Weak C23−H23· · ·O2 H-bonds stabilizing dimers of CFZNH+-DCF−-
EtOH three-component assemblies. Ethanol molecules are in ball and
stick model, carbon atoms of diclofenac anion are in black and H-bonds
are represented by blue dashed lines.
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Chemical formula C27H23Cl2N4 · C14H10Cl2NO2 ·
0.741(CH4O)
C27H23Cl2N4 · C14H10Cl2NO2 ·
C2H6O
C27H23Cl2N4 · C14H10Cl2NO2 ·
C2H6O
C27H23Cl2N4 · C14H10Cl2NO2 ·
C2H3N· 2(H2O)
Mr 793.42 815.59 815.59 846.61
Crystal system, space group Monoclinic, C2/c Triclinic, P1̄ Triclinic, P1̄ Triclinic, P1̄
Temperature (K) 295(2) 295(2) 100(2) 100(2)








α, β , γ (°) 90, 93.438(2), 90 80.291(2), 71.638(2), 71.710(2) 82.032(2), 71.833(3), 74.538(3) 103.558(2), 90.461(2), 105.250(2)
V (Å3) 8013.4(3) 2057.12(10) 1979.61(12) 2052.78(9)
Z 8 2 2 2
No. of measured, independent and
observed [I > 2σ(I)] reflections
23679, 7080, 4722 27818, 7236, 6397 21176, 6977, 6386 18621, 7196, 6969
Rint 0.040 0.024 0.046 0.019
R[F2 > 2σ(F2)], wR(F2), S 0.059, 0.193, 1.02 0.050, 0.146, 1.06 0.057, 0.166, 1.07 0.031, 0.080, 1.03
















Mr 4195.16 2209.89 2209.89 769.52
Crystal system, space group Triclinic, P1̄ Triclinic, P1̄ Triclinic, P1̄ Triclinic, P1̄
Temperature (K) 100(2) 295(2) 100(2) 295(2)








α, β , γ (°) 66.238(3), 89.969(3), 86.658(3) 73.502(4), 77.404(4), 73.540(4) 73.629(3), 76.913(3), 73.271(3) 84.423(3), 67.963(4), 66.662(4)
V (Å3) 5060.5(3) 2859.7(2) 2752.92(19) 1876.21(16)
Z 1 1 1 2
No. of measured, independent and
observed [I > 2σ(I)] reflections
53166, 17765, 13730 28672, 10049, 6767 28107, 9723, 7857 17078, 6630, 5192
Rint 0.069 0.051 0.038 0.037
R[F2 > 2σ(F2)], wR(F2), S 0.060, 0.171, 1.03 0.052, 0.160, 1.02 0.035, 0.090, 1.03 0.048, 0.141, 1.03









Chemical formula C27H23Cl2N4 · C14H10Cl2NO2 ·
C14H11Cl2NO2
C27H23Cl2N4 · C14H10Cl2NO2 ·
C14H11Cl2NO2 · 2(C2H3N)
C27H23Cl2N4 · C14H10Cl2NO2 ·
C14H11Cl2NO2 · C4H8O2
C27H23Cl2N4 · C14H10Cl2NO2 ·
C14H11Cl2NO2
Mr 1065.66 1147.77 1153.76 1065.66
Crystal system, space group Triclinic, P1̄ Triclinic, P1̄ Triclinic, P1̄ Triclinic, P1̄
Temperature (K) 295(2) 295(2) 295(2) 295(2)








α, β , γ (°) 101.568(2), 105.173(2), 94.286(2) 74.882(7), 61.685(8), 64.227(7) 76.043(2), 61.975(3), 63.541(3) 89.161(2),70.570(2), 69.693(2)
V (Å3) 2620.06(10) 2839.6(4) 2820.07(16) 2559.79(12)
Z 2 2 2 2
No. of measured, independent and
observed [I > 2σ(I)] reflections
26706, 9218, 8043 27894, 10010, 7543 27162, 9942, 8898 25042, 9036, 7679
Rint 0.022 0.032 0.022 0.025
R[F2 > 2σ(F2)], wR(F2), S 0.050, 0.141, 1.05 0.050, 0.159, 1.08 0.042, 0.122, 1.05 0.045, 0.129, 1.04
CCDC number 2032496 2032497 2032498 2032499
positions, both of which allow O3−H· · ·O1 interaction between
EtOH and diclofenac anion while at 100 K the same interac-
tion is observed but EtOH is not disordered. At both temper-
atures, diclofenac anion and clofaziminium interact through bi-
furcated charge-assisted H-bonds (N4−H4· · ·O2, N3−H3· · ·O2,
N4−H4· · ·O1 and N3−H3· · ·O1, Table S2†and Figure 4 (a)). A
D11(2) motif between ethanol and diclofenac anion as well as
an intramolecular H-bond (S11(7) motif) in diclofenac anion are
also observed (O3−H3OB· · ·O1 and N5−H5· · ·O2 respectively,
Table S2†and Figure 4 (a)). Dimers of CFZNH+-DCF−-EtOH
three-component assemblies are stabilized through weak H-bonds
(C23−H23· · ·O2, Table S2†and Figure 4 (b)). PXRD pattern of
the powder obtained by liquid-assisted grinding of CFZ with DCF
(in 1:1 molar ratio) and with EtOH as solvent corresponds to the
calculated pattern of CFZNH+-DCF−-EtOH (1:1:1) (Figure S3
(b)†). This powder was analyzed by TG/DSC (Figure S4†) that
revealed a weight loss of 5.6% which is consistent with calcu-
lated EtOH content (5.6%). Only one endothermic event, asso-
ciated with salt melting and solvent evaporation was observed at
113 °C. Such a high temperature of desolvatation suggests that
EtOH is strongly bound to diclofenac anion (Figure S4†and Ta-
ble 2). This is in accordance with the O3· · ·O1 distance (between
2.672(3) and 2.82(1) Å) observed in the structure, which is char-
acteristic of strong H-bond, as defined by Desiraju and Steiner39.
Table 2 Melting point temperatures of reported crystalline phases. Pow-
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3.1.1.3 CFZNH+-DCF−-MeCN-H2O (1:1:1:2) solvated dihy-
drated salt crystallizes in space group P1̄ (Tables 1 and S1†).
One clofaziminium cation, one diclofenac anion, two water and
one acetonitrile molecules constitute the asymmetric unit. A
R12(7) motif is observed between clofaziminium and diclofenac
(N4−H4· · ·O1 and N3−H3· · ·O1 charge-assisted H-bonds, Table
S2†, Figure 5 (a)). An intramolecular N5−H5· · ·O1 H-bond is
also present within the diclofenac anion. Water molecules bridge
diclofenac anion and clofaziminium through O3−H3OA· · ·O2,
O4−H4OB· · ·O3 and O4−H4OA· · ·N2 H-bonds (Table S2†), form-
ing 8-component clusters (2 clofaziminium cations, 2 diclofenac
anions and 4 water molecules, Figure 5 (b) and (c)). These 8-
component clusters are extended along a-axis thanks to water
tetramers (R44 (8) motif, O3−H3OB· · ·O4 and O4−H4OB· · ·O3,
Table S2†, Figure 5 (c)).
Fig. 5 (a) H-bonds between clofaziminium, diclofenac and water in
CFZNH+-DCF−-MeCN-H2O (1:1:1:2), (b) 8-component clusters sta-
bilized by O3−H3OA· · ·O2, O4−H4OB· · ·O3 and O4−H4OA· · ·N2 H-
bonds and (c) chains of 8-component clusters along a-axis (one 8-
component cluster is colored in orange). H-bonds are represented by
blue dashed lines.
3.1.1.4 CFZNH+-DCF−-SAL-H2O (4:4:9:1) solvated hy-
drated salt crystallizes in P1̄ space group (Tables 1 and
S1†). The asymmetric unit contains two clofaziminium cations,
two diclofenac anions, 4.5 salicylaldehyde and a half water
molecules (one salicylaldehyde and the water are located on
an inversion center). Clofaziminium cations interact with
diclofenac anions through charge-assisted H-bonds (R12(7) motif,
N4−H4· · ·O1 and N3−H3· · ·O1, as well as N8−H8· · ·O3 and
N9−H9· · ·O3, Table S2†and Figure 6 (a)). Intramolecular
H-bonds are observed within diclofenac anions (N5−H5· · ·O1
and N10−H10· · ·O3, Table S2†). Two salicylaldehyde molecules
are H-bonded, through their phenol moiety, to diclofenac
anion (O5S−H5OS· · ·O2 as well as O7T−H7OT· · ·O4, Table
S2†and Figure 6 (a)). Other solvent molecules are disordered
and have their phenol moiety oriented to allow intramolec-
ular H-bonds (O9U−H9OU· · ·O10U, O9V−H9OV· · ·O10V;
O11W−H11W· · ·O12W, O11X−H11X· · ·O12X and
O13Y−H13Y· · ·O14Y, Table S2†and Figure 6 (b)). The wa-
ter molecule interacts with the salicylaldehyde molecule located
on an inversion center through O15−H15O· · ·O13Y (Table S2†),
which is H-bonded to diclofenac anion (C29−H29B· · ·O13Y,
Table S2†). Chains along a-axis are stabilized by weak
Fig. 6 (a) H-bonds between clofaziminium, diclofenac anion and salicy-
laldehyde molecules. H atoms not involved in strong H-bonds are omit-
ted for clarity. Salicylaldehyde molecules are in ball and stick model,
carbon atoms of the salicylaldehyde molecule located on an inversion
center are coloured in cyan (other disordered SAL molecule are omit-
ted)). (b) Labelling of atoms involved in weak H-bonds in the struc-
ture of CFZNH+-DCF−-SAL-H2O (4:4:9:1) (salicylaldehyde molecules
are represented in wireframe model and H atoms not involved in strong
H-bonds are omitted for clarity). (c) Weak H-bonds between diclofenac
anions (C38−H38· · ·O2 and C79−H79· · ·O4) stabilize chains along a-
axis (salicylaldehyde molecules are omitted for clarity). Carbon atoms
of diclofenac anion are in black and H-bonds are represented by blue
dashed lines.
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H-bonds between diclofenac anions (C38−H38· · ·O2 and
C79−H79· · ·O4, Table S2†and Figure 6 (c)). Several weak H-
bonds are also observed between clofazimine and salicylaldehyde
molecules (C1−H1· · ·O12W, C18−H18· · ·O6S, C55−H55· · ·O8T,
C61−H61A· · ·O7T and C28W−H28W· · ·O5S, Table S2†).
Weak H-bonds are also observed between two CFZNH+
cations (C14−H14· · ·N2, C25−H25· · ·Cl6, C59−H59· · ·N7 and
C66−H66· · ·Cl2, Table S2†).
3.1.1.5 CFZNH+-DCF−-PPP (2:2:5) solvated salt crystallizes
in P1̄ space group (Tables 1 and S1†). The asymmetric unit
contains one clofaziminium cation, one diclofenac anion, and
2.5 propiophenone molecules (one PPP is located on an in-
version center). The structure of this solvated salt was de-
termined at 295 K and at 100 K. Same interactions are ob-
served at both temperatures, but PPP molecules are disordered
at 295 K). Clofaziminium cation and diclofenac anion interact
through N3−H3· · ·O1 and N4−H4· · ·O1 charge-assisted H-bonds
(Table S2†and Figure 7 (a)). Two propiophenone molecules inter-
act with clofaziminium through weak H-bonds (C15−H15· · ·O3
and C18−H18· · ·O4, Table S2†and Figure 7(a)). Clofaziminium
Fig. 7 (a) H-bonds (blue dashed lines) between clofaziminium, diclofenac
anion and propiophenone molecules (PPP whose oxygen atom is la-
belled O5 is located on an inversion center) and (b) π-cation interaction
(black dashed line) between clofazimine and PPP (centroid in red and
plane in blue). PPP molecules are in ball and stick model, carbon atoms
of diclofenac anion are in black.
cations are stacked in a head-to-tail fashion (centroid-centroid
distance of 3.519(1) Å, interplanar distance of 3.430(1) Å and
horizontal displacement of 0.788 Å (planes and centroids were
calculated using atoms C5 C6 C11 C12)). Moreover, a cation-
π interaction is observed between iminium moiety of CFZNH+
and one propiophenone molecule (vertical distance: 3.719 Å (be-
tween N4+ and the plane passing through C54 C55 C56 C57 C58
and C59) and horizontal displacement of 0.837 Å, Figure 7(b)).
3.1.1.6 CFZNH+-DCF− (1:1) salt crystallizes in space group
P1̄ (Tables 1 and S1†) with one clofaziminium cation and one
diclofenac anion in the asymmetric unit. Clofaziminium interacts
with diclofenac anion through charge-assisted H-bond (R12(7) mo-
tif, N4−H4· · ·O1 and N3−H3· · ·O1, Table S2†, Figure 8). An in-
tramolecular H-bond is observed N5−H5· · ·O2, Table S2†within
diclofenac anion. Interestingly, in this structure, the carboxylate
of diclofenac anion is almost coplanar to the iminophenazine moi-
ety of clofazimine (angle between planes passing through N4-C9-
C8-N3 and O1-C28-O2-C29 is only 14.3°, Table 3) which is not the
case in solvated structures (angles between the same planes are
comprised between 83.2° and 62.5°, Table 3). This orientation
results in a supplementary H-bond between clofaziminium and
diclofenac (N3−H3· · ·O2 Table S2†, Figure 8). Clofaziminium
cations are stacked in a head-to-tail fashion (Figure 8, centroid-
centroid distance: 3.592(2) Å, orthogonal projection distance:
3.443(1) Å and horizontal offset of 1.026 Å, with centroids and
planes calculated from C5 C6 C11 and C12 atoms). This crys-
talline phase can also be obtained by liquid-assisted grinding of
CFZ with DCF (in 1:1 molar ratio) with EtOAc as solvent (Figure
S3 (c)†).
Fig. 8 (a) H-bonds between clofaziminium and diclofenac anion in
CFZNH+-DCF− (1:1) and (b) π-π stacking between clofaziminium (cen-
troids in red and planes in blue). Carbon atoms of diclofenac anion are
in black. H-bonds are represented by blue dashed lines.
Melting point of this unsolvated salt was determined as 186 °C
by DSC analysis (Figure S4†and Table 2). Interestingly, this unsol-
vated salt has a smaller packing coefficient than the solvated 1:1
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Table 3 Packing coefficient of the determined structures (at 295 K unless stated otherwise in the table) and angles between planes passing through N4-
C9-C8-N3 atoms of clofaziminium cations and O1-C28-O2-C29 atoms of diclofenac anions.*Angle between planes passing through N8-C49-C50-N9
atoms of second clofaziminium cation and O3-C69-O4-C70 atoms of second diclofenac anion.
Structure Packing coefficient Angle between N4-C9-C8-N3 and O1-C28-O2-C29 planes (°)
CFZNH+-DCF−-MeOH (1:1:0.74) 0.661 83.0
CFZNH+-DCF−-EtOH (1:1:1) 0.658 73.3
CFZNH+-DCF−-EtOH (1:1:1) (100 K) 0.675 72.2
CFZNH+-DCF−-MeCN-H2O (1:1:1:2) (100 K) 0.677 64.9
CFZNH+-DCF−-SAL-H2O (4:4:9:1) (100 K) 0.700 74.5; 83.2*
CFZNH+-DCF−-PPP (2:2:5) 0.698 81.3
CFZNH+-DCF−-PPP (2:2:5) (100 K) 0.696 80.9
CFZNH+-DCF− (1:1) 0.653 14.3
CFZNH+-DCF−-DCF (1:1:1) (polymorph I) 0.642 66.8
CFZNH+-DCF−-DCF-MeCN (1:1:1:2) 0.665 63.4
CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) 0.657 62.5
CFZNH+-DCF−-DCF (1:1:1) (polymorph II) 0.660 46.4
salts (Table 3). This is in accordance with the presence of voids
(15.41 Å3, 0.8% of the unit cell volume). This lower packing
efficiency could explain solvent insertion (and so solvate crystal-
lization) when diclofenac anion-solvent or clofaziminium cation-
solvent interactions are possible.
3.1.2 Impact of solvent on crystallization of 1:1 salts
Salts combining clofazimine with diclofenac are, as initially
expected, prone to solvate formation as indicated by the majority
of the structures described in this work. First determined
structure (CFZNH+-DCF−-MeOH (1:1:0.74)) contains toxic
solvent (MeOH), which is H-bonded to diclofenac anion.
To avoid presence of toxic solvent, several options can be con-
sidered. The most evident ones, would be salt preparation with-
out solvent (neat grinding) or with non-toxic/pharmaceutically
accepted solvents (water, ethanol40) or desolvatation of solvated
salts. Grinding clofazimine with diclofenac in 1:1 molar ratio in
absence of solvent as well as in presence of water (LAG H2O)
resulted in a physical mixture of clofazimine with diclofenac
(Figure S3 (h)†), thus not yielding any reaction. Moreover, crys-
tallization experiment in only water as solvent was unsuccessful
because of the low aqueous solubility of clofazimine. Since
water as a solvent turned out to be unsuccessful and complete
desolvatation of CFZNH+-DCF−-MeOH (1:1:0.74) is difficult to
achieve before melting of the powder, another pharmaceutically
accepted solvent, namely ethanol, was chosen. In this case,
solvent crystallization experiment as well as liquid-assisted ball
milling, led to the same solvated salt: CFZNH+-DCF−-EtOH
(1:1:1), in which, as expected, ethanol interacted with DCF−
through H-bond.
To further investigate the parameters influencing the crystal-
lization of (un)solvated salts, another protic solvent of higher
molecular volume, salicylaldehyde (111 Å3 38) was selected. De-
spite their high molecular volume, salicylaldehyde molecules are
included in the structure of CFZNH+-DCF−-SAL-H2O (4:4:9:1).
Interestingly more than one salicylaldehyde molecule as well as
one water molecule have been accommodated in the structure
probably to allow a good packing (this structure turned to have
the best packing coefficient, Table 3). The existence of this
solvate proves that the ability of solvent to interact with solute
via weak interactions may be one of the factors explaining why
even bulky solvents can still be trapped in the crystal.
High molecular volume did not hamper solvent insertion in
the structure, at least for protic solvents that are able to inter-
act with the solute through H-bond. We then focused on apro-
tic solvents. First, we selected acetonitrile (molecular volume of
46 Å3 38). However crystals obtained in these conditions corre-
sponded to CFZNH+-DCF−-MeCN-H2O (1:1:1:2), a solvated hy-
drated salt, unstable at room temperature. Three other aprotic
solvents (N,N-dimethylformamide, 78 Å3, ethylacetate, 91 Å3 and
propiophenone, 136 Å3 38) with larger molecular volumes were
then selected to perform crystallization experiments of CFZ and
DCF in 1:1 molar ratio. A larger molecular volume could poten-
tially hamper solvent inclusion in the structure. However, we still
observed solvate formation: crystals obtained from DMF corre-
sponded to the known clofazimine solvate CFZ-DMF (CSD ref-
code: CEKTER41); crystallization experiments performed in pro-
piophenone led to a solvated salt, CFZNH+-DCF−-PPP (2:2:5)),
despite the absence of H-bond donor on propiophenone. The for-
mation of the propiophenone solvate highlights again the fact that
the molecular volume is not the only parameter affecting solvate
formation, and that the interactions between the solvent and the
solute are of crucial importance as well. In this case, propiophe-
none interacts with clofaziminium through π-cation interaction.
Very interstingly, crystals of CFZNH+-DCF− (1:1) unsolvated salt
could however be obtained in ethylacetate, an aprotic molecule
with a smaller molecular volume than propiophenone. The ab-
sence of the aromatic ring in ethylacetate, in contrast to pro-
piophenone, results in a smaller number of potential interactions
that it can form with clofazimine and thus may explain why ethy-
lacetate is not incorporated into the structure. This unsolvated
salt does not correspond to the crystalline phase appearing upon
desolvatation of CFZNH+-DCF−-MeOH (1:1:0.74), which could
indicate the existence of another polymorph of CFZNH+-DCF−
(1:1).
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3.2 Investigation of CFZ-DCF 1:2 cocrystal of salts
The second part of this work is dedicated to studying whether
diclofenac molecule can bind diclofenac anion instead of the
solvent molecule via O-H· · ·O bond. We followed the same
solvent selection criteria as in the first part and chose the solvents
that would be less likely to be incorporated into the structure.
The addition of a second diclofenac molecule in the system is
expected to generate other types of crystal packings than those
obtained for salts in a 1:1 molar ratio. Therefore, solvents
leading to unsolvated form(s) in the case of 1:1 salts could
potentially lead to solvated salts in a 1:2 molar ratio and vice
versa. The solvents selected for this second part of the study
were therefore restricted to low-boiling aprotic (EtOAc and
MeCN) and non-toxic protic (EtOH) solvents. Indeed, MeCN and
EtOAc could potentially be included in the system if they allow
a more efficient packing, however these two solvents should not
normally interact with the solute (CFZNH+, DCF− and DCF)
through H-bond or stacking. These solvents should therefore
not be strongly bound within the crystal structure and, due to
their low boiling point, may easily evaporate from the solvated
structure if the latter is formed. When a diclofenac molecule is
available in the solution, it should compete with protic solvents
for the diclofenac anion binding site, potentially leading to 1:2
CFZ-DCF forms. However, inclusion of a protic solvent could still
be possible (if its shape and size can be accommodated in the
crystal packing) because DCF molecule also possesses H-bond
acceptor. Although, the potential O-H· · ·O interaction between
DCF molecule and the solvent would be expected to be less
strong with diclofenac molecule than with the anion.
3.2.1 Structural analysis
3.2.1.1 CFZNH+-DCF−-DCF (1:1:1) cocrystal of salt (poly-
morph I) crystallizes in P1̄ space group (Tables 1 and S1†).
The asymmetric unit comprises one clofaziminium cation, one di-
clofenac anion and one diclofenac molecule. Clofaziminium inter-
acts with diclofenac anion through charge-assisted H-bond (R22(9)
motif, N4−H4· · ·O1 and N3−H3· · ·O2, Table S2†, Figure 9 (a)).
Intramolecular H-bonds are observed within diclofenac anion and
molecule (N5−H5· · ·O1 and N6−H6· · ·O4, Table S2†, Figure 9
(a)). Diclofenac anion and molecule interact together through
O3−H3O· · ·O2 H-bond (Table S2†). This interaction is very simi-
lar to the one between diclofenac anion and ethanol in CFZNH+-
DCF−-EtOH (1:1:1). Indeed, even if these two structures are not
isostructural, when clofaziminium and diclofenac anion are over-
laid it can be observed that EtOH has a conformation similar to
the first atoms (H3O, O3, C42 and C43) of diclofenac molecule
(Figure 9 (d)).
All previously described interactions stabilize CFZNH+-DCF−-
DCF assemblies. Two types of dimers of these assemblies, which
are respectively stabilized by C31−H31· · ·O3 and C3−H3A· · ·O3
weak H-bonds (Table S2†, Figure 9 (b) and (c)), are also
observed in the structure of CFZNH+-DCF−-DCF (1:1:1)
cocrystal of salt. π-π stacking interactions are also observed
between clofaziminium cations. The first one occurs between
the phenazine core of two CFZNH+, with a centroid-centroid
distance of 3.669(1) Å, an orthogonal projection distance of
3.413(1) Å and an horizontal offset of 1.345 Å (planes and
centroid calculated using C5 C6 C11 and C12 atoms, Figure 9
(e)). This stacking is further stabilized by C3−H3A· · ·O3 (Figure
9 (c)) weak H-bonds. A second π-π stacking interaction is also
observed between two C19 C20 C21 C22 C23 C24 aromatic
rings of clofaziminium with a centroid-centroid distance of
3.801(1) Å, an orthogonal projection distance of 3.357(1) Å and
an horizontal offset of 1.781 Å (Figure 9 (f)). Finally a C−H· · ·π
interaction is observed between C18−H18 of clofaziminium
and diclofenac molecule (C44 C45 C46 C47 C48 C49) with
a H· · ·centroid distance of 2.59 Å, a C· · ·centroid distance of
3.443(3) Å and a C−H· · ·centroid angle of 153° (Figure 9 (g)).
The powder pattern calculated from SCXRD data corresponds
to the one of the batch powder prepared by LAG EtOH (Figure S3
(d)†). This cocrystal of salt melts at 171 °C (Figure S4†and Table
2).
3.2.1.2 CFZNH+-DCF−-DCF-MeCN (1:1:1:2) solvated cocrys-
tal of salt also crystallizes in space group P1̄ (Tables 1 and S1†).
The asymmetric unit contains one clofaziminium cation, one
diclofenac anion, one diclofenac molecule and two acetonitrile
molecules (one MeCN molecule is disordered). Clofaziminium
and diclofenac anion interact through charge-assisted H-bonds
(R12(7) motif, N4−H4· · ·O1 and N3−H3· · ·O1, Table S2†, Figure
10 (a)). In both diclofenac (anion and molecule) an intramolec-
ular H-bond is observed (N5−H5· · ·O2 and N6−H6· · ·O4,
Table S2†). Molecular diclofenac and diclofenac anion interact
through O3−H3B· · ·O2 H-bond (Table S2†, Figure 10 (a)).
Such H-bonds (N4−H4· · ·O1, N3−H3· · ·O1 and O3−H3B· · ·O2)
stabilize CFZNH+-DCF−-DCF assemblies, which further form
dimers through C38−H38· · ·O4 (Figure 10 (b)). A weak H-
bond, stabilizing chains along a-axis, is also observed between
diclofenac molecules (C43−H43A· · ·O3, Figure 10 (c) and (d)).
This crystalline phase can also be obtained from liquid-assisted
grinding of CFZ and DCF in 1:2 molar ratio and with MeCN as
solvent (LAG) (Figure S3 (e)†).
TG/DSC analysis of CFZNH+-DCF−-DCF-MeCN (1:1:1:2)
(powder obtained by liquid-assisted grinding experiment) reveals
a 6.2% weight loss between 50 and 140 °C on the TG curve (Fig-
ure S4†) which is associated with an endothermic event on the
DSC curve (onset: 93 °C) (Figure S4†and Table 2). These events
can be attributed to desolvatation (calculated MeCN content of
7.2% in CFZNH+-DCF−-DCF-MeCN (1:1:1:2)). The endother-
mic event observed at 157 °C corresponds to the melting of the
desolvated phase and suggests the formation of either an eutec-
tic mixture or of an unsolvated crystalline phase combining CFZ
and DCF (Figure S4†and Table 2). A variable-temperature PXRD
experiment performed on CFZNH+-DCF−-DCF-MeCN (1:1:1:2)
confirmed the formation of a new crystalline phase upon heating
which does not correspond to CFZNH+-DCF−-DCF (1:1:1) poly-
morph I (Figure S6†). Results from variable-temperature PXRD
experiment and DSC/TG analyses suggest the formation of a sec-
ond polymorph of CFZNH+-DCF−-DCF (1:1:1).
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Fig. 9 H-bonds between clofaziminium, diclofenac anion and diclofenac molecule in CFZNH+-DCF−-DCF (1:1:1) polymorph I (a), dimers of CFZNH+-
DCF−-DCF assemblies stabilized through C31−H31· · ·O3 (b) and through C3−H3A· · ·O3 (c). Interaction between DCF molecule and DCF anion in
CFZNH+-DCF−-DCF (1:1:1) polymorph I (grey) is similar to the one between DCF anion and EtOH in CFZNH+-DCF−-EtOH (1:1:1) (green) (d). π-π
stacking between clofaziminium cations (e) and (f) and C−H· · ·π interaction between CFZNH+ and DCF molecule (g). Carbon atoms of diclofenac
anion are in black while those of diclofenac molecule are in orange. H-bonds are represented by blue dashed lines.
3.2.1.3 CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) solvated cocrys-
tal of salt crystallizes in P1̄ space group (Tables 1 and S1†).
The asymmetric unit contains one clofaziminium cation, one di-
clofenac anion, one diclofenac molecule and one ethylacetate
molecule. CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) is isostructural
to CFZNH+-DCF−-DCF-MeCN (1:1:1:2) and the same interac-
tions are observed in both structures (Figure 10(e) and (f)).
CFZNH+-DCF−-DCF-EtOAc (1:1:1:1) is prepared by ball-milling
CFZ and DCF in 1:2 molar ratio in presence of few drops of EtOAc
(Figure S3 (f)†). TG/DSC analysis of the CFZ-DCF 1:2 LAG EtOAc
powder reveals a 5.6% weight loss between 50 and 140 °C, asso-
ciated to an endothermic event on the DSC curve (onset: 73 °C),
indicating desolvatation of CFZNH+-DCF−-DCF-EtOAc (1:1:1:1)
(expected solvent content from SCXRD data: 7.6%). The single
endothermic event observed at 157 °C corresponds to the melting
of the desolvated phase (Figure S4†and Table 2). A PXRD exper-
iment performed on heated powder (130 °C) of CFZNH+-DCF−-
DCF-EtOAc (1:1:1:1) confirmed the formation of a new crys-
talline phase, identical to the one obtained by heating CFZNH+-
DCF−-DCF-MeCN (1:1:1:2) (Figure S3 (g)†).
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Fig. 10 (a) H-bonds between clofaziminium, diclofenac anion and diclofenac molecule in CFZNH+-DCF−-DCF-MeCN (1:1:1:2), (b) dimers of CFZNH+-
DCF−-DCF assemblies (c) diclofenac molecules interact through C43−H43A· · ·O3 H-bond and (d) C43−H43A· · ·O3 H-bond between diclofenac
molecules stabilizes chains along a-axis. Carbon atoms of diclofenac anion are in black while those of diclofenac molecule are in orange. Solvent is in
ball and stick model. H-bonds are represented by blue dashed lines.
3.2.1.4 CFZNH+-DCF−-DCF (1:1:1) cocrystal of salt (poly-
morph II) crystallizes in triclinic P1̄ space group (Tables 1 and
S1†). Single crystals of this unsolvated cocrystal of salt were ob-
tained by recrystallization of CFZ-DCF 1:2 powder (physical mix-
ture) in PEG 200. Charge-assisted H-bonds (R12(7), N3−H3· · ·O1
and N4−H4· · ·O1, Table S2†) are observed between clofazi-
minium and diclofenac anion. The second oxygen atom of
DCF− is involved in a D11(2) H-bond with diclofenac molecule
(O3−H3O· · ·O2, Table S2†). These H-bonds (R12(7) and D11(2))
stabilize CFZNH+-DCF−-DCF assemblies (Figure 11 (a)). Weak
H-bonds between CFZNH+ and DCF molecule (C4−H4· · ·O3, Ta-
ble S2†) stabilize dimers of CFZNH+-DCF−-DCF assemblies (Fig-
ure 11 (b)). A second type of such dimers is stabilized by a weak
H-bond between DCF− and DCF molecule (C38−H38· · ·O4, Table
S2†and Figure 11 (c)). Intramolecular H-bonds in DCF− and DCF
are also observed (N5−H5· · ·O2 and N6−H6· · ·O4, Table S2†and
Figure 11 (a)). In comparison with CFZNH+-DCF−-DCF (1:1:1)
polymorph I, π-π stacking contribution to crystal packing stabi-
lization is less important as there is no stacking between clofazi-
minium nor C−H· · ·π interactions between clofaziminium and di-
clofenac molecule. There is however one π-π stacking interaction
between two diclofenac anions with a centroid-centroid distance
of 3.506(1) Å, an orthogonal projection distance of 3.355(1) Å
and an horizontal offset of 1.017 Å (Figure 11(d), planes and
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Fig. 11 (a) H-bonds between clofaziminium, diclofenac anion and diclofenac molecule in CFZNH+-DCF−-DCF (1:1:1) (polymorph II), (b) clofaziminium
and diclofenac molecule interact through C4−H4· · ·O3, stabilizing a dimer of CFZNH+-DCF−-DCF assemblies (c) diclofenac anion and diclofenac
molecule assemblies and (d) π-π stacking between two DCF− anions. (e) Asymmetric unit overlay of CFZNH+-DCF−-DCF (1:1:1) (carbon atoms in
blue) and of CFZNH+-DCF−-DCF-MeCN (1:1:1:2) (carbons atoms in grey). Carbon atoms of diclofenac anion are in black while those of diclofenac
molecule are in orange (except for part (e) of the Figure). H-bonds are represented by blue dashed lines.
centroids calculated with C36 C37 C38 C39 C40 and C41).
Despite a quite good overlay of the molecules constituting their
asymmetric unit (Figure 11 (e)), CFZNH+-DCF−-DCF-MeCN
(1:1:1:2) and CFZNH+-DCF−-DCF (1:1:1) are not isostructural
as revealed by the crystal packing comparison performed with
Mercury (only 9 molecules over 15 overlay despite distance and
angle tolerance of 30% and 30°). Diclofenac anion orientation is
slightly modified in the unsolvated cocrystal of salt in comparison
to the one observed in CFZNH+-DCF−-DCF-MeCN (1:1:1:2). In-
deed, the angle between the planes passing through N4-C9-C8-N3
atoms of CFZNH+ and through O1-C28-O2-C29 of DCF− is differ-
ent in the two structures (63.44° in CFZNH+-DCF−-DCF-MeCN
(1:1:1:2) vs. 46.41° in CFZNH+-DCF−-DCF (1:1:1)).
VT-PXRD and PXRD data measured after heating CFZNH+-
DCF−-DCF-MeCN (1:1:1:2) and CFZNH+-DCF−-DCF-EtOAc
(1:1:1:1) indicate a phase transformation from the solvated
cocrystal of salts to the CFZNH+-DCF−-DCF (1:1:1) unsol-
vated cocrystal of salt (polymorph II) (Figures S3 (g)†and
S6†). TG/DSC data obtained from CFZNH+-DCF−-DCF-MeCN
(1:1:1:2) indicate that CFZNH+-DCF−-DCF (1:1:1) polymorph
II melts at 157 °C (Figure S4†and Table 2). The difference in melt-
ing point observed between polymorph I (171 °C) and polymorph
II (157 °C), can be partially explained by the fact that there are
more π interactions in polymorph I while intermolecular H-bonds
are of comparable strength in both polymorphs. It is interesting
to notice that polymorph II has however a better packing (higher
density) than polymorph I (packing coefficient of 0.660 vs. 0.642,
density of 1.383 g.cm−3 vs. 1.351 g.cm−3 (data collected at 295 K
for both structures)) (Table 3).
3.2.2 Impact of solvent on crystallization of 1:2 cocrystal of
salts
Changing the clofazimine-diclofenac molecular ratio during crys-
tallization experiment allowed the crystallization of a 1:2 unsol-
vated cocrystal of salt in EtOH, while this solvent previously led to
a solvated 1:1 salt. This result indicates that diclofenac molecule
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can succesfully compete with the solvent for the interaction site
with diclofenac anion. However, preparation of 1:2 cocrystal of
salts did not completely rule out crystallization of solvated forms,
as two solvated phases were obtained in acetonitrile and ethy-
lacetate. Interestingly, crystallization of a 1:2 cocrystal of salt
in EtOAc leads to a solvated form while the same solvent previ-
ously lead to an unsolvated CFZNH+-DCF− (1:1) salt. EtOAc and
MeCN both have a small molecular volume that can be accommo-
dated in the structure if packing allows. However, as expected no
strong interactions exist between EtOAc or MeCN and the solutes
(CFZNH+, DCF− and DCF).
TG/DSC analysis of these two solvated cocrystal of salts
(CFZNH+-DCF−-DCF-MeCN (1:1:1:2), CFZNH+-DCF−-DCF-
EtOAc (1:1:1:1)) revealed a weight loss between 50 and 100 °C
and a melting point around 157 °C (Figure S4†). A phase trans-
formation, probably associated with desolvatation (and forma-
tion of an unsolvated cocrystal of salt combining CFZ and DCF),
was identified by PXRD experiments (Figures S6†and S3 (g)†).
The powder diffraction pattern obtained after desolvatation of
CFZNH+-DCF−-DCF-MeCN (1:1:1:2) or CFZNH+-DCF−-DCF-
EtOAc (1:1:1:1) does not correspond to the one of CFZNH+-
DCF−-DCF (1:1:1) (polymorph I)) (Figures S6†and S3 (g)†),
which could be the indication of the existence of a second poly-
morph of CFZNH+-DCF−-DCF (1:1:1). To verify this hypothe-
sis, we have tried to obtain single crystals of this new unsolvated
crystalline phase using other solvents that cannot be incorporated
into the structure. We selected short chain polymers such as PEG
(average MW: 200 g/mol and 400 g/mol) and polycaprolactone
triol (average MW: 300 g/mol) as recrystallization solvents be-
cause of their higher molecular weight and also because of their
molecular ‘flexibility’ in comparison to salicylaldehyde and pro-
piophenone which previously led to solvated salts. Few single
crystals of CFZNH+-DCF−-DCF (1:1:1) (polymorph II) cocrystal
of salt were obtained in PEG (average MW: 200 g/mol). Com-
parison of the calculated powder pattern of CFZNH+-DCF−-DCF
(1:1:1) (polymorph II) with the one obtained after variable-
temperature PXRD experiment performed on CFZNH+-DCF−-
DCF-MeCN (1:1:1:2) confirmed desolvatation and phase trans-
formation that were inferred from VT-PXRD and TG/DSC experi-
ments.
4 Conclusions
Clofaziminium : diclofenac system is a great example of structural
variety that can be reached when a clever solvent selection is ap-
plied to explore various crystalline forms. As expected, diclofenac
anion is able to interact with protic solvent molecules through H-
bonds, leading to the crystallization of solvated drug-drug salts
of clofazimine and diclofenac. Protic and aprotic solvents of in-
creasing molecular volumes were taken in order to understand
how solvent impacts crystallisation of clofazimine and diclofenac.
When facing probable solvate formation, the potential solute-
solvent interactions can be more relevant than the size of the
solvent. For example, the unsolvated CFZNH+-DCF− (1:1) salt
crystallized only in ethylacetate, an aprotic solvent having a
lower molecular volume than another selected solvent, propio-
phenone. Despite its high molecular volume, propiophenone
was incorporated into the structure owing to π interactions,
resulting in the corresponding solvated salt. A particular feature
of the CFZNH+-DCF− (1:1) unsolvated structure is that the
carboxylate of DCF− is almost coplanar to CFZNH+. It is, to the
best of our knowledge, the first time that this specific carboxylate
orientation is reported in a clofaziminium salt. These results
highlight the importance of considering potential solute-solvent
interactions not only in terms of H-bond interactions, but also
other weak interactions such as probable π interactions.
Changing the clofazimine to diclofenac ratio from 1:1 to 1:2
allowed an extra diclofenac molecule to compete for the bind-
ing site with the protic solvent molecules. More particularly,
diclofenac anion succesfully beated EtOH for the H-bond inter-
action on diclofenac anion resulting in an unsolvated cocrystal
of salt (CFZNH+-DCF−-DCF (1:1:1) polymorph I) with the 1:2
clofazimine to diclofenac molar ratio. The second polymorph
of CFZNH+-DCF−-DCF (1:1:1) emerged from desolvatation of
CFZNH+-DCF−-DCF-MeCN (1:1:1:2) and CFZNH+-DCF−-DCF-
EtOAc (1:1:1:1). The latter underlines that undesired solvated
forms can potentially give access to other desired structures. Re-
crystallization using unconventional solvents such as short chain
polymers exhibiting good fluidity, high molecular flexibility and
high molecular weight can also be an option to avoid solvent in-
clusion into the structure, as illustrated by the successful growth
of CFZNH+-DCF−-DCF (1:1:1) (polymorph II) in PEG 200.
Changing the drug:drug ratio in the structure expectedly
affects the physico-chemical properties of the corresponding
solid forms, for instance, the melting point of the CFZNH+-DCF−
(1:1), 186 °C whereas those of CFZNH+-DCF−-DCF (1:1:1)
polymorph I and II are 171 °C and 157 °C respectively.
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9 A. Bērzinš, A. Kons, K. Saršūns, S. Belyakov and A. Actinš,
Crystal Growth & Design, 2020, 20, 5767–5784.
10 K. Smokrović and V. Stilinović, CrystEngComm, 2020, 22,
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